Skip to Main Content

An official website of the United States government

Artificial Intelligence-Based Pathological Model for Predicting Biochemical Recurrence in Prostate Cancer: a Multicenter Study

Principal Investigator
Name
Rui Chen
Degrees
M.D.
Institution
Shanghai Jiao Tong University School of Medicine
Position Title
associate chief physician
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCOI-1486
Initial CDAS Request Approval
Feb 26, 2024
Title
Artificial Intelligence-Based Pathological Model for Predicting Biochemical Recurrence in Prostate Cancer: a Multicenter Study
Summary
Prostate cancer (PCa), the most frequently diagnosed malignancy in males, ranks fifth in cancer-induced mortality. Every year, this disease strikes over 1.4 million new people, which is a serious public health risk. Following radical prostatectomy, an increase in prostate-specific antigen was observed in 30-40% of patients, indicating a recurrence of disease. Patients who experienced PSA over 0.2 ng/mL two or more times following a prostatectomy were considered to have had a biochemical recurrence (BCR).
BCR has a strong predictive value since it is strongly linked to metastasis and cancer recurrence, which negatively affect patient outcomes and lower survival rates. A more effective way to focus adjuvant treatment and give patients a better follow-up plan is through accurate biochemical relapse prediction in patients. Our study aimed to develop a model for predicting biochemical recurrence in prostate cancer based on clinical and pathology WSI slices, in order to provide more accurate and personalized follow-up guidance for patients after radical prostatectomy for prostate cancer.
Aims

1.To accurately identify the tumor regions on digital slides.
2.To accurately predict the pathological grade of tumor on digital slides.
3.To develop a model for predicting biochemical recurrence in prostate cancer based on clinical and digital pathology slides.
4.To provide more accurate and personalized follow-up guidance for patients after radical prostatectomy for prostate cancer.
5.To investigate the possible associations between clinical, pathological, and molecular alterations.

Collaborators

Zijian Song, Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China
Qianwen Zhang, Department of Radiology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Wenhui Zhang, Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Na Ta, Department of Pathology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Yan Zhu, Department of Pathology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Longxin Deng, Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Han Wu, Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Lingxuan Zhu, Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Yancheng Lai, Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Yang Yang, Department of Clinical Laboratory, Nanjing Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
Wei Zhang, Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Rui Zhou, Department of Pathology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China